Publicaciones en colaboración con investigadores/as de Harvard Medical School (9)

2023

  1. Neoadjuvant palbociclib plus either giredestrant or anastrozole in oestrogen receptor-positive, HER2-negative, early breast cancer (coopERA Breast Cancer): an open-label, randomised, controlled, phase 2 study

    The Lancet Oncology, Vol. 24, Núm. 9, pp. 1029-1041

2022

  1. ANTES Program: One Year on

    Archivos de Bronconeumologia

  2. The Effect of Clusters of Double Triggering and Ineffective Efforts in Critically Ill Patients

    Critical Care Medicine, Vol. 50, Núm. 7, pp. E619-E629

  3. [Translated article] ANTES Program: One Year on

    Archivos de Bronconeumologia

2019

  1. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 8, pp. 618-628

  2. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

    The Lancet Diabetes and Endocrinology, Vol. 7, Núm. 12, pp. 899-911

2015

  1. Asynchronies during mechanical ventilation are associated with mortality

    Intensive Care Medicine, Vol. 41, Núm. 4, pp. 633-641

2013

  1. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus

    New England Journal of Medicine, Vol. 369, Núm. 14, pp. 1317-1326

2011

  1. Randomized trial of alendronate plus vitamin D3 versus standard care in osteoporotic postmenopausal women with vitamin D insufficiency

    Calcified Tissue International, Vol. 88, Núm. 6, pp. 485-494